LBRX

+ Watchlist + Portfolio

LB Pharmaceuticals Inc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $48.94
52-Week Range: $13.36 – $49.97
Market Cap: $1.52B
P/E (TTM): —
EPS (TTM): -4.93
Dividend Yield: —

Advanced Metrics

Price/Book: 4.08
PEG Ratio: —
Return on Equity: -50.00%
Return on Assets: -29.98%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 15.08
Debt/Equity: 0.02
Total Debt: $5.22M
Free Cash Flow: $-53.92M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.20B

LBRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.35M	$7.84M	$51.17M	$16.74M
Selling, General & Admin	$1.46M	$3.53M	$13.66M	$13.66M
Operating Expenses	$2.81M	$11.38M	$64.83M	$30.40M
Operating Income	-$2.81M	-$11.38M	-$64.83M	-$30.40M
EBITDA	-$12.19M	-$1.45M	-$64.74M	-$30.08M
Pretax Income	-$14.35M	-$6.27M	-$63.10M	-$25.20M
Income Tax	$1.00K	$1.00K	$1.00K	$1.00K
Net Income	-$14.35M	-$6.28M	-$63.10M	-$25.20M
Diluted EPS	-4.05	-1.77	-17.82	-3.13
Diluted Shares	22.44M	22.44M	22.44M	8.05M

LBRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$21.40M	$14.98M	$22.98M	$250.17M
Current Assets	$21.49M	$45.63M	$28.88M	$308.43M
Total Assets	$21.49M	$45.66M	$33.53M	$312.93M
Current Liabilities	$469.00K	$2.61M	$8.11M	$7.44M
Long-Term Debt	$24.15M	—	—	—
Total Debt	$24.15M	$0.00	$3.70M	$3.57M
Total Liabilities	$50.30M	$80.13M	$128.09M	$11.62M
Retained Earnings	-$34.95M	-$41.22M	-$104.32M	-$129.53M
Shareholders' Equity	-$28.81M	-$34.47M	-$94.55M	$301.31M
Working Capital	$21.02M	$43.03M	$20.77M	$300.99M
Net Debt	$2.74M	—	—	—

LBRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$2.73M	-$12.09M	-$53.05M	-$35.21M
Capital Expenditure	—	-$25.00K	-$769.00K	-$52.00K
Free Cash Flow	-$2.73M	-$12.12M	-$53.82M	-$35.26M
Depreciation & Amortisation	$2.00K	$4.00K	$91.00K	$321.00K
Stock-Based Compensation	$431.00K	$295.00K	$3.16M	$4.19M
Investing Cash Flow	$123.00K	-$28.01M	$23.23M	-$39.89M
Financing Cash Flow	$22.96M	$33.68M	$38.31M	$302.56M
Net Change in Cash	$20.36M	-$6.42M	$8.50M	$227.47M

LBRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.42M	$2.42M	$2.42M	$8.48M	$14.64M
Selling, General & Admin	$3.01M	$2.44M	$2.83M	$5.39M	$7.46M
Operating Expenses	$6.43M	$4.86M	$5.25M	$13.87M	$22.10M
Operating Income	-$6.43M	-$4.86M	-$5.25M	-$13.87M	-$22.10M
EBITDA	-$6.35M	-$4.78M	-$5.17M	-$13.79M	-$22.02M
Pretax Income	-$5.31M	-$4.87M	-$3.56M	-$11.47M	-$19.05M
Income Tax	$0.00	$0.00	$0.00	$1.00K	$0.00
Net Income	-$5.31M	-$4.87M	-$3.56M	-$11.47M	-$19.05M
Diluted EPS	-0.24	—	-0.61	-0.45	-0.67
Diluted Shares	22.44M	—	5.81M	25.41M	28.24M

LBRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$22.98M	$14.22M	$269.74M	$250.17M	$320.68M
Current Assets	$28.88M	$14.78M	$316.40M	$308.43M	$389.07M
Total Assets	$33.53M	$19.25M	$320.75M	$312.93M	$393.48M
Current Liabilities	$8.11M	$3.91M	$6.65M	$7.44M	$10.91M
Total Debt	$3.70M	$3.76M	$3.67M	$3.57M	$3.47M
Total Liabilities	$128.09M	$123.12M	$10.53M	$11.62M	$14.79M
Retained Earnings	-$104.32M	-$114.50M	-$118.06M	-$129.53M	-$148.58M
Shareholders' Equity	-$94.55M	-$103.87M	$310.22M	$301.31M	$378.69M
Working Capital	$20.77M	$10.88M	$309.75M	$300.99M	$378.17M

LBRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.13M	-$5.60M	-$3.37M	-$18.10M	-$23.29M
Capital Expenditure	-$21.00K	—	—	-$40.00K	-$32.00K
Free Cash Flow	-$8.15M	-$5.59M	-$3.37M	-$18.14M	-$23.32M
Depreciation & Amortisation	$79.00K	$76.00K	$81.00K	$85.00K	$82.00K
Stock-Based Compensation	$634.00K	$335.00K	$881.00K	$2.34M	$2.57M
Investing Cash Flow	$4.98M	$9.00K	-$44.84M	-$40.00K	-$32.00K
Financing Cash Flow	$0.00	$0.00	$303.73M	-$1.17M	$93.83M
Net Change in Cash	-$3.15M	-$5.59M	$255.52M	-$19.31M	$70.51M

Market Snapshot

About

LB Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs. The company's pipeline includes drug candidates targeting various therapeutic areas with an emphasis on oncology, rare diseases, or specialty pharmaceuticals. LB Pharmaceuticals conducts clinical trials and works toward regulatory approval for its investigational medicines.